Abstract
Netarsudil, a rho kinase inhibitor, has recently acquired approval for use in adults in the United States to lower intraocular pressure (IOP) in patients with glaucoma. There remains limited data on the effectiveness and safety profile of Netarsudil in children.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have